<DOC>
	<DOCNO>NCT00003573</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness etoposide plus radiation therapy follow combination chemotherapy treat child newly diagnose advanced medulloblastoma .</brief_summary>
	<brief_title>Etoposide Plus Radiation Therapy Followed Combination Chemotherapy Treating Children With Newly Diagnosed Advanced Medulloblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Assess response rate toxicity oral etoposide radiotherapy child newly diagnose high stage medulloblastoma . - Compare response rate toxicity patient historical control patient register POG # 9031 . - Estimate 2-year event-free survival overall survival patient . - Evaluate toxicity dose intensive chemotherapy oral etoposide , cisplatin , cyclophosphamide , vincristine follow craniospinal irradiation patient . OUTLINE : Patients begin treatment within 1 month surgery . Patients receive 6 week radiotherapy head spine , boost posterior fossa sit metastasis . Patients also receive 2 course oral etoposide daily 3 week concurrent immediately follow radiotherapy ( week 1-3 5-7 ) . Patients receive adjuvant chemotherapy consist cisplatin IV every 4 week 3 course begin week 11 , oral etoposide daily 21 day every 4 week 3 course ( week 11 , 15 , 19 ) , cyclophosphamide IV day 1 2 filgrastim ( G-CSF ) SQ daily least 10 day every 4 week 8 course ( week 23-51 ) , vincristine IV day 1 , 8 , 15 every 4 week 8 course ( week 23-51 ) . Patients follow every 3 month 1 year , every 4 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 48 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically diagnose advanced ( high grade ) childhood medulloblastoma Residual disease least 1.5 cm2 size MRI CT scan OR Evidence CNS extraneural metastasis PATIENT CHARACTERISTICS : Age : 3 21 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : SGPT le 5 time normal Bilirubin le 1.5 mg/dL Renal : Creatinine le 1.7 mg/dL OR Creatinine clearance great 70 mL/min Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Prior corticosteroid allow Radiotherapy : No prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>untreated childhood medulloblastoma</keyword>
</DOC>